Attributing CD62Lhigh OVA-specific CD8+ T cells with a greater capacity to provide longer lasting tumor protection relates to their lymphoid migratory properties and proliferative potential when re-confronted with antigen in the context of tumor. The gene discussed is CD8A; the disease is neoplasm.